CD4 T-helper cells

A long read from the University of Cambridge...

The need for a HIV vaccine is still pressing. Its advantages over anti-retroviral drugs are obvious – prevention could lead to the eradication of HIV.

In 2009, a clinical trial in Thailand found that an experimental vaccine against HIV lowered the rate of human infection by 31 per cent.

While promising, there was a significant problem: the vaccine did not offer long-lasting protection because the immune response it generated was very short-lived.

Now, University of Cambridge scientists have helped to discover why – and unlocked a potential solution that gives renewed hope of a long-lasting, effective vaccine.


Featured Posts
Recent Posts
Search By Tags
Follow Us
  • Facebook Classic
  • Twitter Classic
  • Google Classic